Dyne Therapeutics (NASDAQ:DYN) Research Coverage Started at Scotiabank

Posted by Defense World Staff on Mar 10th, 2025

Scotiabank assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report issued on Friday, Marketbeat reports. The brokerage issued a sector outperform rating and a $50.00 price objective on the stock.

DYN has been the topic of several other research reports. Piper Sandler cut their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Friday, February 28th. Robert W. Baird began coverage on Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, HC Wainwright cut their target price on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.75.

Get Our Latest Stock Analysis on DYN

Dyne Therapeutics Stock Up 1.3 %

Shares of DYN opened at $12.40 on Friday. Dyne Therapeutics has a 12-month low of $11.62 and a 12-month high of $47.45. The firm has a market capitalization of $1.40 billion, a PE ratio of -3.48 and a beta of 1.11. The stock’s fifty day simple moving average is $15.80 and its 200-day simple moving average is $26.30.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. Analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,387 shares of company stock worth $142,789. 20.77% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new position in Dyne Therapeutics during the third quarter valued at approximately $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the third quarter valued at approximately $36,000. US Bancorp DE boosted its position in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics during the fourth quarter valued at approximately $50,000. Finally, KBC Group NV boosted its position in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.